Turkey signed a deal with Sinovac for 50 million doses of the vaccine. The first three million doses are scheduled to arrive Monday in Turkey,
Mr. Koca said. Mr. Koca said Turkey would also get 4.5 million doses of the Pfizer-BioNTech vaccine by the end of March.
Around 1 million doses are expected to arrive at the end of January, he said.
CoronaVac, as Sinovac calls its vaccine, is made from killed coronaviruses.
The method is one of the oldest ones for making vaccines,
used by Jonas Salk in the 1950s
to make a vaccine against polio.
After viruses are inactivated with chemicals,
they cannot make people sick,
but they can provoke the immune system to make antibodies that can provide long-term protection against live viruses.
Turkish officials announced Thursday that a
vaccine from the Chinese company Sinovac has an efficacy rate of 91.25 percent,
but the finding was based on preliminary results from a small clinical trial and none of the data was published in a journal or posted online.
Sinovac’s mission is to Supply Vaccines to Eliminate Human Diseases.
To achieve these objectives, Sinovac focuses on research, development, manufacturing and marketing of human-use and animal-use vaccines. The Company also provides services for diseases control and prevention, collaborating with the Chinese governments at the national, state and local levels.
BEIJING--Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China,
today announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.
On July 3, 2020, the Brazilian National Regulatory Agency,
Anvisa, granted approval to a
phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by
Sinovac Life Sciences Co., Ltd. ( or “Sinovac LS”, previously known as Sinovac Research and Development Co., Ltd. or
“Sinovac R&D”), a wholly owned subsidiary of the Company, in Brazil.
This trial aims to be a pivotal study to support the licensure of this product.
Anvisa’s process review included manufacturing and clinical information generated by Sinovac,
and a clinical development plan and trial protocol developed by Butantan.
The agency fast-tracked the application due to the public health emergency which took approximately two weeks to conclude.
The review was conducted at the highest standards as Anvisa is a full member of the International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use (“ICH”)
and qualified as a full functional regulatory agency for the World Health Organization (“WHO”) prequalification process.
This study will recruit nearly 9,000 healthcare professionals working in COVID-19 specialized facilities in twelve clinical sites located in several states in Brazil.
The inclusion of participants is scheduled to start this month after ethical approval is obtained from each clinical site.
"The phase III clinical trial approval is a demonstration that the Sinovac and Butantan partnership is an efficient collaboration to move forward offering hope to save lives worldwide,"
commented Dr. Dimas Covas, Director of Instituto Butantan.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “We are pleased to advance to Phase III trials with Butantan,
which will allow us one step further to our commitment to developing vaccines for global use and to our mission of supplying vaccines to eliminate human diseases.”
Sinovac LS initiated the development of an inactivated vaccine against COVID-19 (named CoronaVac) on January 28th, 2020.
Preclinical study results were published in the peer-reviewed academic journal Science.
On April 13th, 2020 the National Medical Products Administration (“NMPA”) granted approval to conduct phase I and II clinical trials in China.
The phase I and II trials commenced on April 16, 2020 in Jiangsu Province. China. A group of healthy adults aged 18-59 years old were vaccinated with a 0, 14 day schedule.
Preliminary phase I/II results were recently reported. There was no serious adverse event after vaccinating a total of 743 volunteers in the trials,
demonstrating a good safety profile for the vaccine candidate.
Over 90% seroconversion was observed in the phase II clinical trial 14 days after completion of a two-dose vaccination at day 0 and day 14.
A Phase II study on elderly adults is being conducted which will be followed by child and adolescent groups.
The phase II trial is expected to be completed at the end of 2020. The Company has partnered with several companies outside of China for phase III efficacy studies.
About Sinovac LS
Sinovac Life Sciences Co., Ltd., (or “Sinovac LS”), previously known as Sinovac Research & Development Co., td.,
is a research-based company incorporated in 2009 that conducts human vaccine research, development, manufacturing,
and sales. Sinovac LS is a wholly owned subsidiary of Sinovac Biotech (Hong Kong) Limited. It develops several human vaccines,
including vaccines against pneumonia, DTaP, Hib, hepatitis B vaccines and combo vaccines containing DTaP and Hib. Sinovac LS was granted 12 patents in vaccine technologies in China.
Sinovac Life Sciences is the developer of CoronaVac, an inactivated COVID-19 vaccine candidate,
and will be the marketing authorization holder of CoronaVac in China with a vaccine production license from China National Medical Products Administration (NMPA).
About Instituto Butantan
Instituto Butantan is the main producer of immunobiological products and vaccines in Brazil. Instituto Butantan carries out scientific missions
domestically and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations.
The Institute collaborates with other agencies of the São Paulo State Secretariat of Health and the Brazilian Ministry of Health for the
improvement of overall health in Brazil. It acts in partnership with various universities, research institutions, pharmaceutical companies,
and entities such as the Bill & Melinda Gates Foundation for the achievement of its institutional objectives.
For more information please visit the Institute website at http://www.butantan.gov.br or contact the press office at (+55 11) 2627-9606 / 9428 or email to email@example.com.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research,
development, manufacturing and commercialization of vaccines that protect against human infectious diseases.
Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza,
Quadrivalent Influenza vaccine (“QIV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps.
Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017.
The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine,
which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program.
The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine,
pneumococcal polysaccharides vaccine, and a SARS-CoV-2 (commonly referred to as COVID-19) vaccine.
Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets.
The Company is registering its products in over 30 countries outside of China. For more information please see the
Company’s website at http://www.sinovac.com.
Safe Harbor Statement
This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements.
These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements.
In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or that could be filed against it by others.
Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price should its rights plan have been triggered.
Sinovac Biotech Ltd.
Bill Zima +1-646-308-1707
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
|SVA News: シノバックのオミクロン株を含むCOVID-19ワクチンの臨床試験の開始がチリで承認される||09/07/2022 07:57:00 AM|
|SVA News: SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile||09/06/2022 03:20:00 PM|
|SVA News: SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19||09/06/2022 10:03:00 AM|
|SVA News: SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile||09/06/2022 06:00:00 AM|
|SVA News: シノバックのCOVID-19ワクチンが香港で生後6カ月以上の小児への使用が承認される||08/05/2022 02:19:00 PM|